Table of Contents Author Guidelines Submit a Manuscript
Journal of Thyroid Research
Volume 2017, Article ID 4259183, 11 pages
https://doi.org/10.1155/2017/4259183
Clinical Study

Thyrotoxic Atrial Fibrillation: Factors Associated with Persistence and Risk of Ischemic Stroke

Department of Medicine & Geriatrics, Caritas Medical Centre, 111 Wing Hong Street, Sham Shui Po, Kowloon, Hong Kong

Correspondence should be addressed to Cheuk-Lik Wong; kh.moc.oohay@msinairalucsum

Received 6 September 2017; Accepted 21 November 2017; Published 12 December 2017

Academic Editor: Fausto Bogazzi

Copyright © 2017 Cheuk-Lik Wong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. M. Grais and J. R. Sowers, “Thyroid and the heart,” American Journal of Medicine, vol. 127, no. 8, pp. 691–698, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. G. J. Kahaly and W. H. Dillmann, “Thyroid hormone action in the heart,” Endocrine Reviews, vol. 26, no. 5, pp. 704–728, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Dahl, S. Danzi, and I. Klein, “Thyrotoxic cardiac disease,” Current Heart Failure Reports, vol. 5, no. 3, pp. 170–176, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. I. Klein and S. Danzi, “Thyroid disease and the heart,” Circulation, vol. 116, no. 15, pp. 1725–1735, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Fazio, E. A. Palmieri, G. Lombardi, and B. Biondi, “Effects of thyroid hormone on the cardiovascular system,” Recent Progress in Hormone Research, vol. 59, pp. 31–50, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Klein and K. Ojamaa, “Thyroid hormone and the cardiovascular system,” The New England Journal of Medicine, vol. 344, no. 7, pp. 501–509, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Biondi, “How could we improve the increased cardiovascular mortality in patients with overt and subclinical hyperthyroidism?” European Journal of Endocrinology, vol. 167, no. 3, pp. 295–299, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Brandt, A. Green, L. Hegedüs, and T. H. Brix, “A critical review and meta-analysis of the association between overt hyperthyroidism and mortality,” European Journal of Endocrinology, vol. 165, no. 4, pp. 491–497, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Metso, A. Auvinen, J. Salmi, H. Huhtala, and P. Jaatinen, “Increased long-term cardiovascular morbidity among patients treated with radioactive iodine for hyperthyroidism,” Clinical Endocrinology, vol. 68, no. 3, pp. 450–457, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Metso, P. Jaatinen, H. Huhtala, A. Auvinen, H. Oksala, and J. Salmi, “Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism,” The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 6, pp. 2190–2196, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. J. A. Franklyn, M. C. Sheppard, and P. Maisonneuve, “Thyroid function and mortality in patients treated for hyperthyroidism,” Journal of the American Medical Association, vol. 294, no. 1, pp. 71–80, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. C.-W. Siu, V. Pong, X. Zhang et al., “Risk of ischemic stroke after new-onset atrial fibrillation in patients with hyperthyroidism,” Heart Rhythm, vol. 6, no. 2, pp. 169–173, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. P.-H. Chan, J. Hai, C.-Y. Yeung et al., “Benefit of Anticoagulation Therapy in Hyperthyroidism-Related Atrial Fibrillation,” Clinical Cardiology, vol. 38, no. 8, pp. 476–482, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia. Report of a WHO/IDF Consultation, World Health Organization, Geneva, Switzerland, 2006.
  15. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation, World Health Organization, Geneva, Switzerland, 2011.
  16. M. Senni, C. M. Tribouilloy, R. J. Rodeheffer et al., “Congestive heart failure in the community: A study of all incident cases in Olmsted county, Minnesota, in 1991,” Circulation, vol. 98, no. 21, pp. 2282–2289, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. S. D. Fihn, J. M. Gardin, J. Abrams et al., “ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,” Journal of the American College of Cardiology, vol. 60, no. 24, pp. 2564–2603, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Kirchhof, S. Benussi, D. Kotecha et al., “2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS,” European Heart Journal, vol. 37, no. 38, pp. 2893–2962, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. R. L. Sacco, S. E. Kasner, J. P. Broderick et al., “2013 An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American heart association/American stroke association,” Stroke, vol. 44, no. 7, pp. 2064–2089, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. G. M. Costongs, R. J. van Oers, B. Leerkens, W. Hermans, and P. C. Janson, “Evaluation of the Abbott automated random, immediate and continuous access immunoassay analyser, the AxSYM,” European Journal of Clinical Chemistry and Clinical Biochemistry, vol. 33, no. 2, pp. 105–111, 1995. View at Google Scholar
  21. M. M. Redfield, S. J. Jacobsen, J. C. Burnett Jr., D. W. Mahoney, K. R. Bailey, and R. J. Rodeheffer, “Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic,” The Journal of the American Medical Association, vol. 289, no. 2, pp. 194–202, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. M. D. Cheitlin, W. F. Armstrong, G. P. Aurigemma et al., “ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography),” Circulation, vol. 108, no. 9, pp. 1146–1162, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. R. M. Lang, M. Bierig, R. B. Devereux et al., “Recommendations for chamber quantification: a report from the American Society of Echocardiography's guidelines and standards committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology,” Journal of the American Society of Echocardiography, vol. 18, no. 12, pp. 1440–1463, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. W. A. Zoghbi, M. Enriquez-Sarano, E. Foster et al., “Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography,” Journal of the American Society of Echocardiography, vol. 16, no. 7, pp. 777–802, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. C.-W. Siu, X.-H. Zhang, and C. Yung, “Hemodynamic changes in hyperthyroidism-related pulmonary hypertension: a prospective echocardiographic study,” The Journal of Clinical Endocrinology Metabolism, vol. 92, no. 5, pp. 1736–1742, 2007. View at Publisher · View at Google Scholar
  26. N. Galiè, M. M. Hoeper, M. Humbert et al., “Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT),” European Heart Journal, vol. 30, no. 20, pp. 2493–2537, 2009. View at Google Scholar · View at Scopus
  27. P. Elliott, B. Andersson, E. Arbustini et al., “Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases,” European Heart Journal, vol. 29, no. 2, pp. 270–276, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Mestroni, B. Maisch, W. J. McKenna et al., “Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy,” European Heart Journal, vol. 20, no. 2, pp. 93–102, 1999. View at Google Scholar · View at Scopus
  29. H. M. Ismail, “Reversible pulmonary hypertension and isolated right-sided heart failure associated with hyperthyroidism,” Journal of General Internal Medicine, vol. 22, no. 1, pp. 148–150, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Cohen and A. Schattner, “Right heart failure and hyperthyroidism: A neglected presentation,” American Journal of Medicine, vol. 115, no. 1, pp. 76-77, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. B. Biondi and G. J. Kahaly, “Cardiovascular involvement in patients with different causes of hyperthyroidism,” Nature Reviews Endocrinology, vol. 6, no. 8, pp. 431–443, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. F. Osman, J. A. Franklyn, R. L. Holder, M. C. Sheppard, and M. D. Gammage, “Cardiovascular Manifestations of Hyperthyroidism Before and After Antithyroid Therapy. A Matched Case-Control Study,” Journal of the American College of Cardiology, vol. 49, no. 1, pp. 71–81, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. W.-S. Yue, B.-H. Chong, X.-H. Zhang et al., “Hyperthyroidism-induced left ventricular diastolic dysfunction: implication in hyperthyroidism-related heart failure,” Clinical Endocrinology, vol. 74, no. 5, pp. 636–643, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Vallabhajosula, S. Radhi, C. Cevik, R. Alalawi, R. Raj, and K. Nugent, “Hyperthyroidism and pulmonary hypertension: An important association,” The American Journal of the Medical Sciences, vol. 342, no. 6, pp. 507–512, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Goland, S. Shimoni, and O. Kracoff, “Dilated cardiomyopathy in thyrotoxicosis,” Heart, vol. 81, no. 4, pp. 444–449, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Boccalandro, F. Boccalandro, P. Orlander, and C. F. Wei, “Severe reversible dilated cardiomyopathy and hyperthyroidism: case report and review of the literature,” Endocrine Practice, vol. 9, no. 2, pp. 140–146, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. P. A. Chandra, A. Vallakati, A. B. Chandra, M. Pednekar, and J. Ghosh, “Repetitive monomorphic ventricular tachycardia as a manifestation of suboptimally treated thyrotoxicosis,” American Heart Hospital Journal, vol. 8, no. 2, pp. E113–E114, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. P. J. Nadkarni, M. Sharma, B. Zinsmeister, L. Wartofsky, and K. D. Burman, “Thyrotoxicosis-induced ventricular arrhythmias,” Thyroid, vol. 18, no. 10, pp. 1111–1114, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Shimizu, S. Koide, J. Y. Noh, K. Sugino, K. Ito, and H. Nakazawa, “Hyperthyroidism and the management of atrial fibrillation,” Thyroid, vol. 12, no. 6, pp. 489–493, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. N. Jayaprasad and F. Johnson, “Atrial fibrillation and hyperthyroidism,” Indian Pacing and Electrophysiology Journal, vol. 5, no. 4, pp. 305–311, 2005. View at Google Scholar · View at Scopus
  41. A. Bielecka-Dabrowa, D. P. Mikhailidis, J. Rysz, and M. Banach, “The mechanisms of atrial fibrillation in hyperthyroidism,” Thyroid Research, vol. 2, no. 1, article 4, 2009. View at Publisher · View at Google Scholar
  42. P. Petersen and J. M. Hansen, “Stroke in thyrotoxicosis with atrial fibrillation,” Stroke, vol. 19, no. 1, pp. 15–18, 1988. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Iwasaki, M. Naka, K. Hiramatsu et al., “Echocardiographic studies on the relationship between atrial fibrillation and atrial enlargement in patients with hyperthyroidism of Graves' disease,” Cardiology, vol. 76, no. 1, pp. 10–17, 1989. View at Publisher · View at Google Scholar · View at Scopus
  44. L. Frost, P. Vestergaard, and L. Mosekilde, “Hyperthyroidism and risk of atrial fibrillation or flutter: A population-based study,” JAMA Internal Medicine, vol. 164, no. 15, pp. 1675–1678, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. H. K. Nakazawa, K. Sakurai, N. Hamada, N. Momotani, and K. Ito, “Management of atrial fibrillation in the post-thyrotoxic state,” American Journal of Medicine, vol. 72, no. 6, pp. 903–906, 1982. View at Publisher · View at Google Scholar · View at Scopus
  46. Z. H. Zhou, L. L. Ma, and L. X. Wang, “Risk factors for persistent atrial fibrillation following successful hyperthyroidism treatment with radioiodine therapy,” Internal Medicine, vol. 50, no. 24, pp. 2947–2951, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. G. Casaclang-Verzosa, B. J. Gersh, and T. S. M. Tsang, “Structural and Functional Remodeling of the Left Atrium. Clinical and Therapeutic Implications for Atrial Fibrillation,” Journal of the American College of Cardiology, vol. 51, no. 1, pp. 1–11, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. C.-W. Siu, M.-H. Jim, X. Zhang et al., “Comparison of Atrial Fibrillation Recurrence Rates After Successful Electrical Cardioversion in Patients With Hyperthyroidism-Induced Versus Non-Hyperthyroidism-Induced Persistent Atrial Fibrillation,” American Journal of Cardiology, vol. 103, no. 4, pp. 540–543, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. W. P. Abhayaratna, J. B. Seward, C. P. Appleton et al., “Left atrial size: physiologic determinants and clinical applications,” Journal of the American College of Cardiology, vol. 47, no. 12, pp. 2357–2363, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Nakazawa, D. A. Lythall, J. Noh et al., “Is there a place for the late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation,” European Heart Journal, vol. 21, no. 4, pp. 327–333, 2000. View at Publisher · View at Google Scholar · View at Scopus
  51. J. Heeringa, J. A. Kors, A. Hofman, F. J. A. van Rooij, and J. C. M. Witteman, “Cigarette smoking and risk of atrial fibrillation: The Rotterdam Study,” American Heart Journal, vol. 156, no. 6, pp. 1163–1169, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. A. M. Chamberlain, S. K. Agarwal, A. R. Folsom et al., “Smoking and incidence of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) study,” Heart Rhythm, vol. 8, no. 8, pp. 1160–1166, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. H. F. Lozano and C. N. Sharma, “Reversible pulmonary hypertension, tricuspid regurgitation and right-sided heart failure associated with hyperthyroidism: Case report and review of the literature,” Cardiology in Review, vol. 12, no. 6, pp. 299–305, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. R. J. McDonough, M. S. Moul, D. Beckman, and A. M. Slim, “Isolated right ventricular failure in hyperthyroidism: A clinical dilemma,” Heart International, vol. 6, no. 2, pp. 38–40, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. S. H. Hwang, K. H. Hong, H. M. Noh et al., “Improvement of Severe Tricuspid Regurgitation with Right Heart Failure Associated with Thyrotoxicosis due to Graves' Disease,” Journal of Cardiovascular Ultrasound, vol. 17, no. 1, pp. 22–24, 2009. View at Publisher · View at Google Scholar
  56. M. Bonou, K. M. Lampropoulos, M. Andriopoulou, D. Kotsas, J. Lakoumentas, and J. Barbetseas, “Severe tricuspid regurgitation and isolated right heart failure due to thyrotoxicosis.,” Indian Heart Journal, vol. 64, no. 6, pp. 600–602, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. V. H. Tam and L. M. Fung, “Severe right heart failure in two patients with thyrotoxicosis,” Hong Kong Medical Journal, vol. 14, no. 4, pp. 321–323, 2008. View at Google Scholar
  58. J. Mercé, S. Ferrás, C. Oltra et al., “Cardiovascular abnormalities in hyperthyroidism: A prospective Doppler echocardiographic study,” American Journal of Medicine, vol. 118, no. 2, pp. 126–131, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Q. Najib, K. L. Vinales, S. S. Vittala, S. Challa, H. R. Lee, and H. P. Chaliki, “Predictors for the development of severe tricuspid regurgitation with anatomically normal valve in patients with atrial fibrillation,” Journal of Echocardiography, vol. 29, no. 2, pp. 140–146, 2012. View at Publisher · View at Google Scholar · View at Scopus
  60. S. A. Lubitz, E. J. Benjamin, and P. T. Ellinor, “Atrial Fibrillation in Congestive Heart Failure,” Heart Failure Clinics, vol. 6, no. 2, pp. 187–200, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. L. Oliveros-Ruiz, M. Vallejo, L. F. Diez Canseco, M. Cárdenas, and J. A. G. Hermosillo, “Determinants of thyrotoxic cardiomyopathy recovery,” BioMed Research International, vol. 2013, Article ID 452709, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. R. Nagarakanti and M. Ezekowitz, “Diastolic dysfunction and atrial fibrillation,” Journal of Interventional Cardiac Electrophysiology, vol. 22, no. 2, pp. 111–118, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. M. A. Rosenberg and W. J. Manning, “Diastolic dysfunction and risk of atrial fibrillation: A mechanistic appraisal,” Circulation, vol. 126, no. 19, pp. 2353–2362, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. C.-W. Siu, C.-Y. Yeung, C.-P. Lau, A. W. C. Kung, and H.-F. Tse, “Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism,” Heart, vol. 93, no. 4, pp. 483–487, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. Q. Chen, Y. Yan, L. Zhang, K. Cheng, Y. Liu, and W. Zhu, “Effect of hyperthyroidism on the hypercoagulable state and thromboembolic events in patients with atrial fibrillation,” Cardiology (Switzerland), vol. 127, no. 3, pp. 176–182, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. M.-F. Poulin and R. Doukky, “Hyperthyroid atrial fibrillation: Does it matter for stroke risk?” Cardiology (Switzerland), vol. 128, no. 1, pp. 51–53, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. M. V. L. De Souza, M. M. T. Duarte, C. M. Coeli, and M. Vaisman, “Atrial fibrillation and hyperthyroidism: Relation between transoesophageal markers of a thrombogenic milieu and clinical risk factors for thromboembolism,” Clinical Endocrinology, vol. 76, no. 3, pp. 448–453, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. A. Squizzato, V. E. A. Gerdes, D. P. M. Brandjes, H. R. Büller, and J. Stam, “Thyroid diseases and cerebrovascular disease,” Stroke, vol. 36, no. 10, pp. 2302–2310, 2005. View at Publisher · View at Google Scholar · View at Scopus